Out-licensing
- Out-licensing
- View
Naloxone 0,4 mg/ml ampoule
Opioid receptor antagonist reducing opioid induced respiratory depression
Mechanism of action
Competitive antagonist on opioid reptors. Inhibits opioid induced respiratory depression.
Full description
Strong Opioid-antagonist for postoperative use and in emergency after overdose of e.g. Heroine. Target groups are anaesthetists and hospitals (accident and emergency units). The product is a generic and supplied in packs of 10 ampoules.
Development status
Registered
Patent information
Off patent
Type of business relationship sought
Country specific or regional distribution contract.
Related reports
Market Research Reports provided by reports.iptechex.com
Apr 2011 - 47 pages - $500
Aug 2011 - 48 pages - $500
Dec 2010 - 40 pages - $500
Mar 2011 - 40 pages - $500
Dec 2010 - 35 pages - $500
May 2010 - 111 pages - $5,700
Mar 2011 - 6 pages - $500
Oct 2011 - 102 pages - $500
Mar 2011 - 31 pages - $250
Dec 2010 - 24 pages - $500
Licensing contact
Company details
Orpha Swiss GmbH
OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine
View profileRelated technologies
Related categories
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us